Primary Site >> Colorectal Cancer
Gene >> ALK
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Tumor-associated antigens in polyps and carcinoma of the human large bowel. PMID: 6164469 Ref: Carcinoplacental alkaline phosphatase in malignant and premalignant conditions of the human digestive tract. PMID: 7039085 |
Ref: Wheat bran oil and its fractions inhibit human colon cancer cell growth and intestinal tumorigenesis in Apc(min/+) mice. PMID: 17177503 |
Ref: Anticancer effects of diallyl trisulfide derived from garlic. PMID: 18296348 Ref: Alkenyl group is responsible for the disruption of microtubule network formation in human colon cancer cell line HT-29 cells. PMID: 18515280 |
Ref: Low-fouling poly(N-vinyl pyrrolidone) capsules with engineered degradable properties. PMID: 19719165 Ref: Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. PMID: 19737969 |
Ref: Inhibitors of anaplastic lymphoma kinase: a patent review. PMID: 20961208 |
Ref: Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. PMID: 21076462 Ref: [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]. PMID: 21271476 Ref: 5-alk(en)ylresorcinols as the major active components in wheat bran inhibit human colon cancer cell growth. PMID: 21658963 Ref: Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. PMID: 21889923 |
Ref: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. PMID: 22327622 Ref: KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. PMID: 22797671 Ref: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. PMID: 22845480 Ref: Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. PMID: 23114745 Ref: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. PMID: 23178117 Ref: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. PMID: 23259591 Ref: K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. PMID: 27398239 |
Ref: Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. PMID: 22991232 Ref: Identification of ROS1 rearrangement in gastric adenocarcinoma. PMID: 23400546 Ref: Crizotinib induces PUMA-dependent apoptosis in colon cancer cells. PMID: 23427294 Ref: Companion biomarkers: paving the pathway to personalized treatment for cancer. PMID: 23656699 Ref: Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. PMID: 23876834 Ref: ALK gene amplification is associated with poor prognosis in colorectal carcinoma. PMID: 24129244 Ref: Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. PMID: 24200637 |
Ref: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. PMID: 23493335 Ref: ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. PMID: 24296758 Ref: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PMID: 24691006 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. PMID: 25392179 Ref: PMID: 25905152 |
Ref: ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma. PMID: 24992173 Ref: Biomarkers for personalized oncology: recent advances and future challenges. PMID: 25468140 Ref: Molecular characterization of WDCP, a novel fusion partner for the anaplastic lymphoma tyrosine kinase ALK. PMID: 25469238 Ref: Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. PMID: 25755678 Ref: The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. PMID: 25926053 Ref: Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. PMID: 26172300 Ref: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. PMID: 26358176 Ref: Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. PMID: 26457764 Ref: Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. PMID: 26468446 Ref: Epstein-Barr virus-associated inflammatory pseudotumor presenting as a colonic mass. PMID: 26477709 Ref: Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. PMID: 26633560 Ref: MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. PMID: 26677401 Ref: Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population. PMID: 26678488 Ref: Incomplete Intestinal Obstruction Caused by a Rare Epithelioid Inflammatory Myofibroblastic Sarcoma of the Colon: A Case Report. PMID: 26705227 Ref: [Companion Diagnostics for Solid Tumors]. PMID: 26995877 |
Ref: ROS1 Kinase Inhibitors for Molecular-Targeted Therapies. PMID: 26438251 Ref: Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. PMID: 26797410 Ref: Diffuse large B-cell lymphoma in colon confounded by prior history of colorectal cancer: A case report and literature review. PMID: 26893766 Ref: Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. PMID: 26933125 Ref: Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. PMID: 26939704 Ref: Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. PMID: 27063727 Ref: MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. PMID: 27325282 Ref: How the lab is changing our view of colorectal cancer. PMID: 27647226 |
Ref: Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. PMID: 28095174 Ref: Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). PMID: 28183697 Ref: Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. PMID: 28368455 Ref: ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. PMID: 28465216 Ref: Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. PMID: 28507204 Ref: The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. PMID: 28675510 Ref: Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient. PMID: 28903424 Ref: In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. PMID: 29125233 Ref: ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. PMID: 29370427 |
Ref: Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. PMID: 29352732 Ref: TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET). PMID: 29581845 Ref: Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. PMID: 29588308 Ref: Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. PMID: 29844865 Ref: Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer. PMID: 29955133 |